By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



34 Commerce Way

Woburn  Massachusetts  01801  U.S.A.
Phone: 781-933-1409 Fax: 781-933-6025




Company News
Former BioVex CEO Who Sold to Amgen (AMGN) for $1 Billion Raises $30 Million for Replimune 9/24/2015 6:15:31 AM
Amgen (AMGN) Raises Presence in Massachusetts With BioVex Buy, Boosts Hiring 3/9/2011 8:19:18 AM
Amgen (AMGN) Completes Acquisition of BioVex 3/7/2011 6:36:10 AM
Amgen (AMGN) to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass for up to $1 Billion 1/25/2011 6:40:41 AM
BioVex to Present at 29th Annual JP Morgan Healthcare Conference 1/5/2011 9:16:31 AM
BioVex Commences OncoVEXGM-CSF Phase 3 Trial in Head and Neck Cancer 12/10/2010 8:41:36 AM
BioVex Announces Publication of Head and Neck Cancer Clinical Trial Results with OncoVEX GM-CSF in the Journal Clinical Cancer Research 8/2/2010 8:21:30 AM
BioVex Appoints Ex Roche (RHHBY) Oncology Head, Kapil Dhingra, to the Board of Directors 7/22/2010 9:19:38 AM
BioVex Appoints Steven Kelly as Chief Commercial Officer 7/1/2010 10:00:59 AM
BioVex Initiates Phase 1 Clinical Trial with Its Genital Herpes Vaccine, ImmunoVEX(HSV2) 3/4/2010 9:11:01 AM